Utilization of the Abbott SARS-CoV-2 IgG II Quant Assay To Identify High-Titer Anti-SARS-CoV-2 Neutralizing Plasma against Wild-Type and Variant SARS-CoV-2 Viruses

There is evidence that COVID-19 convalescent plasma may improve outcomes of patients with impaired immune systems; however, more clinical trials are required. Although we have previously used a 50% plaque reduction/neutralization titer (PRNT(50)) assay to qualify convalescent plasma for clinical tri...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Yi-Chan J., Evans, David H., Robbins, Ninette F., Orjuela, Guillermo, Hu, Queenie, Samson, Reuben, Abe, Kento T., Rathod, Bhavisha, Colwill, Karen, Gingras, Anne-Claude, Tuite, Ashleigh, Yi, Qi-Long, O’Brien, Sheila F., Drews, Steven J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9602363/
https://www.ncbi.nlm.nih.gov/pubmed/36125288
http://dx.doi.org/10.1128/spectrum.02811-22

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9602363/
https://www.ncbi.nlm.nih.gov/pubmed/36125288
http://dx.doi.org/10.1128/spectrum.02811-22

Ejemplares similares